Compounders Research Compare

LENSAR Inc(LNSR)

Medical - Devices · Orlando, FL

$6.69+0.02 (+0.30%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

About LENSAR Inc

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Orlando, FL

150 employees

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Nicholas T. Curtis

View full financials

LENSAR (LNSR) EV/FCF: History & Chart | TGMCharts

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T14:57:40.740Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:57:40.740Z.

Quote observation: 2026-10-06T14:55:30.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 82,163,777
Total debt · period ending 2026-06-30: 2,381,000
Cash · period ending 2026-06-30: 13,565,000
TTM free cash flow · period ending 2026-06-30: -7,328,000

FMP input reference: 4b39d0c73cbdfa69f0b7c8f40e573a317b01c7cc2fd28b7d8d8bae27d2fbb310

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

LNSR EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

LNSR Competitors' EV/FCF Ratio

LENSAR Inc

Current

Market Cap

$82.16M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Acrivon Therapeutics, Inc. Common Stock

Market Cap

$83.46M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MediciNova, Inc.

Market Cap

$83.18M

EV/FCF Ratio

N/A

TTM Avg

97.70x

3Y Avg

97.70x

5Y Avg

97.70x

Citius Oncology, Inc.

Market Cap

$81.02M

EV/FCF Ratio

N/A

TTM Avg

816.68x

3Y Avg

816.68x

5Y Avg

816.68x

Nutriband Inc.

Market Cap

$83.63M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Pulmonx Corporation

Market Cap

$80.04M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Humacyte, Inc.

Market Cap

$84.81M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cognition Therapeutics, Inc.

Market Cap

$84.14M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Atara Biotherapeutics, Inc.

Market Cap

$85.87M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cardiff Oncology, Inc.

Market Cap

$85.94M

EV/FCF Ratio

N/A

TTM Avg

17.26x

3Y Avg

15.52x

5Y Avg

17.05x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
LENSAR Inc (LNSR)	$82.16M	N/A	N/A	N/A	N/A
Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›	$83.46M	N/A	N/A	N/A	N/A
MediciNova, Inc. (MNOV)vs ›	$83.18M	N/A	97.70x	97.70x	97.70x
Citius Oncology, Inc. (CTOR)vs ›	$81.02M	N/A	816.68x	816.68x	816.68x
Nutriband Inc. (NTRB)vs ›	$83.63M	N/A	N/A	N/A	N/A
Pulmonx Corporation (LUNG)vs ›	$80.04M	N/A	N/A	N/A	N/A
Humacyte, Inc. (HUMA)vs ›	$84.81M	N/A	N/A	N/A	N/A
Cognition Therapeutics, Inc. (CGTX)vs ›	$84.14M	N/A	N/A	N/A	N/A
Atara Biotherapeutics, Inc. (ATRA)vs ›	$85.87M	N/A	N/A	N/A	N/A
Cardiff Oncology, Inc. (CRDF)vs ›	$85.94M	N/A	17.26x	15.52x	17.05x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics